Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 4.5% - What's Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price was down 4.5% on Thursday . The company traded as low as $0.31 and last traded at $0.32. Approximately 28,860,322 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 31,034,150 shares. The stock had previously closed at $0.33.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Price Performance

The stock has a market capitalization of $58.68 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $0.23 and a two-hundred day simple moving average of $0.37.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analysts' expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.